Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies

Exclusion Criteria

• •Prior Therapy
• •* Exposure to chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier
• •* Systemic steroids that have not been stabilized to the equivalent of ≤10 mg/day prednisone prior to the start of the study drugs
• •* No other investigational agents are allowed
• •Central nervous system metastases, including lymphomatous meningitis
• •History of allergic reactions to Pralatrexate or Romidepsin
• •Uncontrolled intercurrent illness
• •Pregnant women
• •Nursing women
• •Current malignancy or history of a prior malignancy, as outlined in the protocol
• •Patient known to be Human Immunodeficiency Virus (HIV)-positive
• •Active Hepatitis A, Hepatitis B, or Hepatitis C infection